Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research • 01/11/23
3 Remarkable Growth Stocks That Could Climb 39% to 46%, According to Wall StreetThe Motley Fool • 01/07/23
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/21/22
2 Top Growth Stocks Down 42.6% and 68.5% to Buy Before They Rebound in 2023The Motley Fool • 12/02/22
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACTGlobeNewsWire • 10/31/22
Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to DeclineZacks Investment Research • 10/26/22
Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/02/22
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein ThrombosisGlobeNewsWire • 08/30/22
Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/27/22
Inari Medical: Fundamentals Soft, Technicals Supportive Of Near-Term Upside CaptureSeeking Alpha • 07/22/22
OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASESPRNewsWire • 06/07/22